Pricing

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Policymakers respond to a crisis and every crisis has to have a villain. Unfortunately, today pharma is the villain.

McCann Health forms new global consultancy

McCann Health forms new global consultancy

By

The consultancy includes Double Helix, which was acquired by McCann in 2012.

Five things for pharma marketers to know: Monday, September 19, 2016

Five things for pharma marketers to know: Monday, September 19, 2016

By

Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study

Five things for pharma marketers to know: Thursday, September 15, 2016

Five things for pharma marketers to know: Thursday, September 15, 2016

By

Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness

Five things for pharma marketers to know: Wednesday, September 7, 2016

Five things for pharma marketers to know: Wednesday, September 7, 2016

By

BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan

CEO: Allergan will limit price increases for branded drugs

CEO: Allergan will limit price increases for branded drugs

By

CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

By

In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.

Five things for pharma marketers to know: Monday, August 29, 2016

Five things for pharma marketers to know: Monday, August 29, 2016

By

Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent

Five things for pharma marketers to know: Friday, August 26, 2016

Five things for pharma marketers to know: Friday, August 26, 2016

By

Sarah Jessica Parker cuts ties with Mylan over pricing controversy; lung-cancer physicians turn to Keytruda; Merck KGaA diversifies its business

Five things for pharma marketers to know: Thursday, August 25, 2016

Five things for pharma marketers to know: Thursday, August 25, 2016

By

Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated

Five things for pharma marketers to know: Wednesday, August 24, 2016

Five things for pharma marketers to know: Wednesday, August 24, 2016

By

Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Five things for pharma marketers to know: Friday, July 29, 2016

Five things for pharma marketers to know: Friday, July 29, 2016

By

England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development

Five things for pharma marketers to know: Thursday, July 21, 2016

Five things for pharma marketers to know: Thursday, July 21, 2016

By

The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers

Five things for pharma marketers to know: Thursday, July 7, 2016

Five things for pharma marketers to know: Thursday, July 7, 2016

By

EpiPen price hikes led to syringe use; states with medical marijuana laws have drops in drug spending; Pfizer and Merck KGaA start ovarian cancer trial

Five things for pharma marketers to know: Tuesday, June 7, 2016

Five things for pharma marketers to know: Tuesday, June 7, 2016

By

Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database

Five things for pharma marketers to know: Monday, June 6, 2016

Five things for pharma marketers to know: Monday, June 6, 2016

By

Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug

Five things for pharma marketers to know: Wednesday, June 1, 2016

Five things for pharma marketers to know: Wednesday, June 1, 2016

By By

WHO finds poor countries are paying too much for HCV drugs; Gilead faces a lawsuit over an HIV drug; BioMarin to stop developing Duchenne treatment

Five things for pharma marketers to know: Thursday, May 12, 2016

Five things for pharma marketers to know: Thursday, May 12, 2016

By

Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart

Reframing the Debate: Why Drug Spending Can Lower Costs

Reframing the Debate: Why Drug Spending Can Lower Costs

Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off

Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

By

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

Five things for pharma marketers to know: Wednesday, April 27, 2016

Five things for pharma marketers to know: Wednesday, April 27, 2016

By

Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula

Zika Crisis Stresses Need for Pharma Industry

Zika Crisis Stresses Need for Pharma Industry

By

When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.

Five things for pharma marketers to know: Thursday, April 14, 2016

Five things for pharma marketers to know: Thursday, April 14, 2016

By

Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license

Five things for pharma marketers to know: Tuesday, April 12, 2016

Five things for pharma marketers to know: Tuesday, April 12, 2016

By

California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

By

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, April 1, 2016

Five things for pharma marketers to know: Friday, April 1, 2016

By

GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance

Another physician group raises concerns about DTC

Another physician group raises concerns about DTC

By

The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.

Five things for pharma marketers to know: Monday, March 21, 2016

Five things for pharma marketers to know: Monday, March 21, 2016

By

Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development

Five things for pharma marketers to know: Friday, March 18, 2016

Five things for pharma marketers to know: Friday, March 18, 2016

By

OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader

OPINION

Email Newsletters